Literature DB >> 21330274

Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.

Sean P David1, Elaine C Johnstone, Michael Churchman, Paul Aveyard, Michael F G Murphy, Marcus R Munafò.   

Abstract

INTRODUCTION: Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice.
METHODS: New and previously published smoking cessation genetic association results of 30 candidate gene polymorphisms genotyped for participants in two transdermal nicotine replacement clinical trials based in UK general practices, which employed an intention to analyze approach.
RESULTS: By this high bar, one of the polymorphisms (COMT rs4680) was robust to correction for multiple comparisons. Moreover, future research directions are outlined; and lessons learned as well as best-practice models for designing, analyzing, and translating results into clinical practice are proposed.
CONCLUSIONS: The results and lessons learned from this general practice-based pharmacogenetic research programme provide transportable insights at the transition to the second generation of pharmacogenetic and genomic investigations of smoking cessation and its translation to primary care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330274      PMCID: PMC3107615          DOI: 10.1093/ntr/ntq246

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  91 in total

1.  Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority.

Authors:  M Raw; A McNeill; R West
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

2.  Setting priorities for genomic research.

Authors:  Wade Berrettini; Laura Bierut; Thomas J Crowley; Joseph F Cubells; Joseph Frascella; Joel Gelernter; John K Hewitt; Mary Jeanne Kreek; Herb Lachman; Mark Leppert; Ming D Li; Pamela Madden; Cindy Miner; Jonathan D Pollock; Ovide Pomerleau; John P Rice; Joni L Rutter; David Shurtleff; Gary E Swan; Jay A Tischfield; Ming Tsuang; George R Uhl; Michael Vanyukov; Nora D Volkow; Kay Wanke
Journal:  Science       Date:  2004-06-04       Impact factor: 47.728

Review 3.  The genetic basis for smoking behavior: a systematic review and meta-analysis.

Authors:  Marcus Munafò; Taane Clark; Elaine Johnstone; Michael Murphy; Robert Walton
Journal:  Nicotine Tob Res       Date:  2004-08       Impact factor: 4.244

4.  The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population.

Authors:  E C Johnstone; P Yudkin; S E Griffiths; A Fuller; M Murphy; R Walton
Journal:  Addict Biol       Date:  2004 Sep-Dec       Impact factor: 4.280

Review 5.  Smoking cessation: evidence based recommendations for the healthcare system.

Authors:  M Raw; A McNeill; R West
Journal:  BMJ       Date:  1999-01-16

6.  Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking.

Authors:  C Lerman; P G Shields; D Main; J Audrain; J Roth; N R Boyd; N E Caporaso
Journal:  Pharmacogenetics       Date:  1997-12

7.  Mortality from smoking worldwide.

Authors:  R Peto; A D Lopez; J Boreham; M Thun; C Heath; R Doll
Journal:  Br Med Bull       Date:  1996-01       Impact factor: 4.291

8.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

Authors:  H M Lachman; D F Papolos; T Saito; Y M Yu; C L Szumlanski; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1996-06

9.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.

Authors:  Jingshan Chen; Barbara K Lipska; Nader Halim; Quang D Ma; Mitsuyuki Matsumoto; Samer Melhem; Bhaskar S Kolachana; Thomas M Hyde; Mary M Herman; Jose Apud; Michael F Egan; Joel E Kleinman; Daniel R Weinberger
Journal:  Am J Hum Genet       Date:  2004-09-27       Impact factor: 11.025

Review 10.  The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.

Authors:  Robert M Bilder; Jan Volavka; Herbert M Lachman; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2004-11       Impact factor: 7.853

View more
  12 in total

1.  APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset.

Authors:  Raj K Kalapatapu; Kevin L Delucchi
Journal:  Am J Drug Alcohol Abuse       Date:  2013-06-28       Impact factor: 3.829

2.  A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback.

Authors:  M R Lee; C L Gallen; T J Ross; P Kurup; B J Salmeron; C A Hodgkinson; D Goldman; E A Stein; M A Enoch
Journal:  Genes Brain Behav       Date:  2013-04-11       Impact factor: 3.449

3.  Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment.

Authors:  Alexandra Elizabeth Shields; Mehdi Najafzadeh; Anna Boonin Schachter
Journal:  Per Med       Date:  2013-11-01       Impact factor: 2.512

4.  Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Authors:  Tae-Hwi Schwantes-An; Juan Zhang; Li-Shiun Chen; Sarah M Hartz; Robert C Culverhouse; Xiangning Chen; Hilary Coon; Josef Frank; Helen M Kamens; Bettina Konte; Leena Kovanen; Antti Latvala; Lisa N Legrand; Brion S Maher; Whitney E Melroy; Elliot C Nelson; Mark W Reid; Jason D Robinson; Pei-Hong Shen; Bao-Zhu Yang; Judy A Andrews; Paul Aveyard; Olga Beltcheva; Sandra A Brown; Dale S Cannon; Sven Cichon; Robin P Corley; Norbert Dahmen; Louisa Degenhardt; Tatiana Foroud; Wolfgang Gaebel; Ina Giegling; Stephen J Glatt; Richard A Grucza; Jill Hardin; Annette M Hartmann; Andrew C Heath; Stefan Herms; Colin A Hodgkinson; Per Hoffmann; Hyman Hops; David Huizinga; Marcus Ising; Eric O Johnson; Elaine Johnstone; Radka P Kaneva; Kenneth S Kendler; Falk Kiefer; Henry R Kranzler; Ken S Krauter; Orna Levran; Susanne Lucae; Michael T Lynskey; Wolfgang Maier; Karl Mann; Nicholas G Martin; Manuel Mattheisen; Grant W Montgomery; Bertram Müller-Myhsok; Michael F Murphy; Michael C Neale; Momchil A Nikolov; Denise Nishita; Markus M Nöthen; John Nurnberger; Timo Partonen; Michele L Pergadia; Maureen Reynolds; Monika Ridinger; Richard J Rose; Noora Rouvinen-Lagerström; Norbert Scherbaum; Christine Schmäl; Michael Soyka; Michael C Stallings; Michael Steffens; Jens Treutlein; Ming Tsuang; Tamara L Wall; Norbert Wodarz; Vadim Yuferov; Peter Zill; Andrew W Bergen; Jingchun Chen; Paul M Cinciripini; Howard J Edenberg; Marissa A Ehringer; Robert E Ferrell; Joel Gelernter; David Goldman; John K Hewitt; Christian J Hopfer; William G Iacono; Jaakko Kaprio; Mary Jeanne Kreek; Ivo M Kremensky; Pamela A F Madden; Matt McGue; Marcus R Munafò; Robert A Philibert; Marcella Rietschel; Alec Roy; Dan Rujescu; Sirkku T Saarikoski; Gary E Swan; Alexandre A Todorov; Michael M Vanyukov; Robert B Weiss; Laura J Bierut; Nancy L Saccone
Journal:  Behav Genet       Date:  2015-09-21       Impact factor: 2.805

Review 5.  Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Authors:  Michael Mamoun; Andrew W Bergen; Jennifer Shieh; Anna Wiggins; Arthur L Brody
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

Review 6.  Biomarkers to optimize the treatment of nicotine dependence.

Authors:  Robert A Schnoll; Frank T Leone
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

Review 7.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

Review 8.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

9.  Cardiovascular responses induced by Catalase Inhibitior into the Fourth Cerebral Ventricle is changed in Wistar rats exposed to sidestream cigarette smoke.

Authors:  Vitor E Valenti; Luiz Carlos de Abreu; Fernando L A Fonseca; Jose-Luiz Figueiredo; Fernando Adami; Celso Ferreira
Journal:  Int J Health Sci (Qassim)       Date:  2013-06

10.  Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.

Authors:  Jennifer B McClure; Gary E Swan; Jackie St John; Randy Fauver; Harold S Javitz; Andrew W Bergen; Denise Nishita; Raymond Niaura; Marcus R Munafò; Sean P David
Journal:  Nicotine Tob Res       Date:  2012-09-04       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.